ABSTRACT
The Covid-19 pandemic and other recent disruptions in the early 2020s led to sections in the business press blaming just-in-time (JIT) practices for operational failings. Consequently, there are calls for moving away from JIT toward holding more inventory as preparation against future disruptions, which is referred to as just-in-case. The academic community is also divided. Some scholars argue that JIT is not resilient, while others maintain that JIT can continue providing superior performance even with disruptions. Motivated by this debate, we discuss various misconceptions about JIT that underlie this debate. Furthermore, we present different ways to adapt JIT for turbulent environments and argue that companies can improve their supply chain performance if JIT supply chain segments are chosen fittingly—even more so—during disruptions. © 2023 The Authors. Production and Operations Management published by Wiley Periodicals LLC on behalf of Production and Operations Management Society.
ABSTRACT
Purpose: Supply chains must rebuild for resilience to respond to challenges posed by systemwide disruptions. Unlike past disruptions that were narrow in impact and short-term in duration, the Covid pandemic presented a systemic disruption and revealed shortcomings in responses. This study outlines an approach to rebuilding supply chains for resilience, integrating innovation in areas critical to supply chain management. Design/methodology/approach: The study is based on extensive debates among the authors and their peers. The authors focus on three areas deemed fundamental to supply chain resilience: (1) forecasting, the starting point of supply chain planning, (2) the practices of supply chain risk management and (3) product design, the starting point of supply chain design. The authors' debated and pooled their viewpoints to outline key changes to these areas in response to systemwide disruptions, supported by a narrative literature review of the evolving research, to identify research opportunities. Findings: All three areas have evolved in response to the changed perspective on supply chain risk instigated by the pandemic and resulting in systemwide disruptions. Forecasting, or prediction generally, is evolving from statistical and time-series methods to human-augmented forecasting supplemented with visual analytics. Risk management has transitioned from enterprise to supply chain risk management to tackling systemic risk. Finally, product design principles have evolved from design-for-manufacturability to design-for-adaptability. All three approaches must work together. Originality/value: The authors outline the evolution in research directions for forecasting, risk management and product design and present innovative research opportunities for building supply chain resilience against systemwide disruptions. © 2023, Emerald Publishing Limited.
ABSTRACT
The success of the messenger RNA-based COVID-19 vaccines of Moderna and Pfizer/BioNTech marks the beginning of a new chapter in modern medicine. However, the rapid rise of mRNA therapeutics has resulted in a regulatory framework that is somewhat lagging. The current guidelines either do not apply, do not mention RNA therapeutics, or do not have widely accepted definitions. This review describes the guidelines for preclinical biodistribution studies of mRNA/siRNA therapeutics and highlights the relevant differences for mRNA vaccines. We also discuss the role of in vivo RNA imaging techniques and other assays to fulfill and/or complement the regulatory requirements. Specifically, quantitative whole-body autoradiography, microautoradiography, mass spectrometry-based assays, hybridization techniques (FISH, bDNA), PCR-based methods, in vivo fluorescence imaging, and in vivo bioluminescence imaging, are discussed. We conclude that this new and rapidly evolving class of medicines demands a multi-layered approach to fully understand its biodistribution and in vivo characteristics.